List of Excipients in Branded Drug DURACLON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Institutional LLC	DURACLON	clonidine hydrochloride	67457-218	SODIUM CHLORIDE

Last updated: July 29, 2026

DURACLON excipient strategy and commercial opportunities for generic and reformulation developers

DURACLON is positioned as a reformulation and lifecycle-extension platform where excipient selection can drive product differentiation on dissolution, tablet integrity, moisture/temperature stability, and patient-tolerability. Commercial opportunity clusters center on (1) excipient-led bioequivalence risk reduction for generic entry, (2) line extensions through altered-release or improved manufacturability, and (3) cost-down via excipient substitution that preserves CQAs.

If DURACLON’s formulation is not a single fixed reference but is marketed in multiple dosage forms (and strengths), then excipient strategy becomes a multi-asset exercise, because bioequivalence and stability are formulation- and method-of-manufacture-specific.

---

What excipients are typically used in DURACLON and how do they affect performance?

Excipient strategy is best treated as a mapping exercise from excipient function to formulation CQAs:

What excipient roles matter most for oral solids?

• Direct compression and tableting aids
  • Microcrystalline cellulose (MCC) for compressibility and robust hardness.
  • Lactose monohydrate/anhydrous for dilution and flow.
  • Starch (pregelatinized) or modified starch for binding and disintegration balance.
• Binder and tablet strength
  • Povidone (PVP) grades for wet granulation/binder functionality.
  • Hydroxypropyl cellulose (HPC) for binder action with controlled dissolution impact.
• Disintegrants
  • Croscarmellose sodium (CCS) or sodium starch glycolate for fast disintegration.
  • Cross-linked PVPP or low-substitution disintegrants depending on taste and stability.
• Lubricants
  • Magnesium stearate and alternatives such as stearic acid or sodium stearyl fumarate to reduce lubrication-related dissolution slow-down.
• Coatings
  • Opadry-style film coatings for moisture protection and tablet surface quality.
  • Enteric polymers if pH dependence is desired (not assumed without confirmation).
• Moisture and stability excipients
  • Antioxidants (if the API is oxidation-prone).
  • Desiccants or packaging changes when water sensitivity exists.

What performance characteristics change with excipient selection?

• Dissolution rate: lubricant level, binder grade, particle size distribution, disintegrant type and level.
• Bioavailability risk: for poorly soluble APIs, excipient-driven wetting agents and microenvironment pH can matter.
• Robustness under manufacturing variation: granulation end-point, compression force, mixing time.
• Shelf-life stability: moisture uptake and polymorphic changes can be excipient-mediated.

---

Which excipient strategies reduce bioequivalence risk for DURACLON generics?

For generic developers, the commercial objective is to meet BE with minimal reformulation. Excipient strategy focuses on lowering variability and tightening control of dissolution-linked attributes.

How to reduce dissolution variability

1. Lock the disintegrant system
   • Use the same disintegrant family and similar particle size distribution when possible.
   • If different, calibrate dissolution-through-validation (QbD) rather than assume interchangeability.
2. Manage lubricant effects
   • Lubrication can reduce wetting and slow dissolution.
   • Narrow the target range for magnesium stearate (or select an alternative with lower hydrophobic impact).
3. Keep binder behavior aligned
   • Binder viscosity grade affects granule strength and disintegration.

How to reduce stability variability

• Control water activity and moisture migration via coating system and packing.
• Use excipients with documented low hygroscopicity if the API is moisture sensitive.
• Ensure excipient grade consistency across batches to avoid lot-to-lot dissolution drift.

What commercial differentiation looks like for generics

• “BE-compliant” is the baseline.
• “BE-compliant with lower cost” is the main scale lever.
• If DURACLON is subject to frequent supply constraints, excipient strategy that enables alternative suppliers and shorter lead times can be a market advantage.

---

What formulation patents exist for DURACLON excipients, coatings, and release-control systems?

Patent-driven excipient strategy follows three tracks:

1. Excipients in the independent claim
2. Excipients in dependent claims
3. Process and particle engineering claims that indirectly constrain excipient choice

Patent search logic for DURACLON excipient protection

• Search assignee portfolios for claims covering:
  • “pharmaceutically acceptable excipient”
  • specific disintegrant and lubricant combinations
  • film-coating compositions
  • excipient levels (by weight)
  • granulation and compression parameters linked to dissolution outcomes
• Identify whether claims require:
  • specific excipient ratios
  • excipient particle size ranges
  • coating polymer types and plasticizers

How to use this legally

• For generic entry, the main risk is an active patent that explicitly covers the excipient system or its proportional ranges.
• If excipient composition is not claimed, the next risk layer is process claims tied to excipient handling or granulation endpoint.

---

When does DURACLON lose exclusivity, and how does that change excipient-based competition?

Exclusivity and patent expiration determine timing for excipient-optimized ANDA filings.

Commercial timing framework

• Patent expiration: earliest date when composition and process claims end.
• Regulatory exclusivity:
  • New Chemical Entity (NCE) exclusivity applies only to certain approvals.
  • New Clinical Investigation exclusivity and patent term adjustments can shift practical launch timelines.
• Orange Book-listed exclusivities can delay generic approvals even when patents expire.

How excipient strategy changes by launch window

• Pre-expiration: focus on BE strategy that avoids lock-up by non-infringement or “safe” pathways if a patent remains.
• Post-expiration: optimize manufacturing cost and supply chain. Excipient cost-down matters most after you can launch without injunction risk.
• Late-cycle: reformulations and fixed-dose combinations can reintroduce competition but still face patent/patent-product coupling.

---

How strong is the DURACLON patent estate for excipient and formulation workarounds?

Patent strength is assessed by claim coverage depth across:

• composition of matter (API),
• formulation composition (API + excipient system),
• method of manufacture (granulation, dry milling, compression parameters),
• method of use,
• and any dependent claim “shelves” that preserve coverage through substitutions.

What constitutes a “high friction” excipient landscape

• Independent claims specifying:
  • a disintegrant type plus level,
  • a binder plus lubricant combination,
  • coating polymer stack,
  • and dissolution targets tied to the excipient system.
• Multiple families filed across jurisdictions, including continuation or divisional strategies.

What constitutes a “low friction” excipient landscape

• Claims limited to API polymorphs and basic manufacturing steps with no explicit excipient list.
• Broad “pharmaceutically acceptable excipient” language without percentage constraints.

---

Which excipient substitutions create the biggest commercial upside for DURACLON line extensions?

Line extensions are the fastest path to revenue lift if patent constraints allow. Excipient-led opportunities usually focus on either usability or cost.

Common high-upside reformulation directions

• Faster disintegration tablet for easier swallowing if current product is patient-critical.
• Improved taste and mouthfeel via coating or disintegration control (for if/when taste masking is part of the current weakness).
• Stability-enhancing coating to reduce degradation-related returns and improve shelf availability.
• Manufacturability improvement:
  • switch from wet granulation to direct compression if the API and excipients permit,
  • or change excipient grades to improve flow and reduce defects.

Commercial lens

• If DURACLON faces recurrent manufacturing constraints, the best ROI excipient change is the one that:
  • increases throughput,
  • reduces batch failure rates,
  • shortens cycle time,
  • and supports broader supplier qualification.

---

What coatings and release-control excipients could be used to reformulate DURACLON?

If DURACLON is an oral solid, coating selection is a major driver of moisture protection and dissolution timing.

Coating strategy map

• Immediate-release film coating
  • polymer level and plasticizer selection affect dissolution and moisture ingress.
• Moisture-barrier coatings
  • reduce water uptake and protect against API degradation.
• Functional coatings
  • pH-dependent or taste-masking coatings can be introduced if allowed by patent landscape and BE requirements.

Where commercial opportunity concentrates

• Multi-strength product lines benefit most from coating optimization that can be scaled across strengths without changing dissolution profiles.

---

What excipient-linked risks appear in DURACLON generic manufacturing and scale-up?

Scale-up risks are often excipient-mediated, not API-mediated.

Key risk nodes

• Granulation endpoint sensitivity to binder viscosity and solution concentration.
• Segregation and blending uniformity to excipient particle size distribution.
• Lubricant distribution affecting dissolution variability across lots.
• Moisture uptake during manufacturing and storage that changes polymorphic behavior.
• Compatibility between API and excipients that can drive discoloration or degradation.

Mitigation that also supports commercial speed

• Vendor qualification for excipient supply and consistent specs.
• Tight in-process controls for blend time, granulation temperature, and drying endpoint.
• Dissolution method robustness during development to avoid BE drift.

---

What patent litigation affects DURACLON excipient and formulation pathways?

Excipient strategy is only relevant if it collides with active litigation outcomes.

How to assess litigation impact quickly (without overreaching)

• Identify whether:
  • the asserted claims are formulation claims including excipients,
  • the court’s preliminary injunction scope restricts manufacturing or generic distribution,
  • the settlement imposes launch design-arounds that specify excipient or process constraints.

Commercial implications of settlement terms

• If settlement includes “carve-out” designs, it can pre-define which excipient systems are acceptable.
• If settlements require date-based non-entry, then excipient work becomes a way to prepare ANDA readiness while waiting.

---

What is the Orange Book status of DURACLON and how does it shape excipient freedom?

Orange Book status determines whether excipient-led workarounds are blocked by:

• listed patents that cover formulation or process,
• listed patent-expiration timing that drives launch date.

Practical pathway logic for generic entrants

• If there is a listed patent that covers the excipient system, Paragraph IV must be paired with:
  • a clear design-around,
  • non-infringement evidence,
  • or an invalidity position.
• If only the API claims remain, excipient selection can be optimized for BE and cost as long as it does not touch protected formulation claim elements.

---

How does DURACLON compare with other excipient-sensitive oral solids in the market?

Oral solids with excipient-driven BE risk typically cluster around:

• poorly soluble APIs,
• systems where disintegration and wetting dominate,
• and products with documented dissolution-based performance differences.

Benchmarking implications

• Use “dissolution-controlled” excipient strategies common in the class:
  • tailored disintegrant,
  • lubricant minimization,
  • binder selection aligned to tablet porosity.

Competitive outcome

• Developers who align excipient systems to dissolution profiles usually reduce BE development cycle time.
• Developers who pursue cost-down without dissolution alignment often face BE iteration risk and delayed commercial timelines.

---

Key tables: excipient levers, performance impact, and BE relevance for DURACLON

Table 1. Excipient levers and likely impact areas

Excipient function	Common candidates	What changes	BE/QA sensitivity
Binder	PVP, HPC	granule strength, disintegration	High (dissolution)
Disintegrant	CCS, sodium starch glycolate	disintegration speed	High
Lubricant	Mg stearate, Na stearyl fumarate	wetting and dissolution	High
Diluent/compressibility	MCC, lactose	tablet porosity, strength	Medium-High
Film coating	polymer + plasticizer	moisture ingress, dissolution delay	Medium-High
Stabilizer/antioxidant	class-specific	degradation rate	Medium

Table 2. Commercial opportunity by lifecycle stage

Stage	Objective	Excipient strategy priority
Pre-patent expiry	BE readiness	align dissolution determinants, minimize risk
Launch preparation	speed and scale	supplier qualification and cost controllability
Post-launch	margin and robustness	cost-down substitutions without dissolution drift
Late lifecycle	line extensions	coating/disintegration improvements if legally available

---

Key Takeaways

• Excipient strategy for DURACLON is a performance and risk-management program focused on dissolution, tablet integrity, and moisture stability.
• For generic entry, the highest-yield excipient levers are disintegrant selection, lubricant control, binder behavior, and coating permeability.
• Commercial opportunity shifts by timing: pre-expiration work reduces BE cycle time; post-expiration work targets scale, supplier flexibility, and cost.
• Patent and Orange Book listings determine whether excipient design-around is feasible or whether formulation constraints drive non-infringement design.
• Litigation and settlements can pre-define acceptable formulations, making excipient work more deterministic than exploratory.

---

FAQs

1) What excipient properties most often drive DURACLON dissolution differences in bioequivalence studies?
Disintegrant action, lubricant level and grade, and binder viscosity affecting tablet porosity are the main dissolution drivers.

2) Can lubricant substitution (eg, magnesium stearate vs alternative lubricants) lower DURACLON bioequivalence risk?
Yes when substitution preserves dissolution profile; lubricant hydrophobicity and mixing/order matter.

3) What excipients are most likely to affect DURACLON moisture uptake and shelf-life stability?
Hygroscopic excipients in the core and coating permeability under high humidity are the main stability variables.

4) How should reformulators structure excipient changes to support DURACLON line extensions without triggering new patent exposure?
Map excipient elements to Orange Book-listed formulation/process patents and avoid any claim-required excipient ratios and combinations.

5) What manufacturing controls most directly prevent excipient-related lot variability for DURACLON tablets?
Tight controls on granulation endpoint, blend uniformity, compression force window, and lubricant mixing time reduce dissolution drift.

---

References

1. FDA. “Drug Products and (for Drugs) Lists of Prescribing Information.” Orange Book. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. “Bioequivalence Studies Submitted in ANDAs.” Guidance for Industry. U.S. Food and Drug Administration. https://www.fda.gov/
3. FDA. “Immediate Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes.” Guidance for Industry. U.S. Food and Drug Administration. https://www.fda.gov/